These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 35624002)

  • 21. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
    Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
    Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of targeting MDSCs in tumor microenvironment.
    Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
    Front Immunol; 2022; 13():990463. PubMed ID: 36131911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microglia/macrophages express alternative proangiogenic factors depending on granulocyte content in human glioblastoma.
    Blank A; Kremenetskaia I; Urbantat RM; Acker G; Turkowski K; Radke J; Schneider UC; Vajkoczy P; Brandenburg S
    J Pathol; 2021 Feb; 253(2):160-173. PubMed ID: 33044746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroinflammation in Glioblastoma: The Role of the Microenvironment in Tumour Progression.
    Nóbrega AHL; Pimentel RS; Prado AP; Garcia J; Frozza RL; Bernardi A
    Curr Cancer Drug Targets; 2024; 24(6):579-594. PubMed ID: 38310461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.
    Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P
    J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
    Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
    Front Immunol; 2021; 12():637053. PubMed ID: 34108959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.
    Huang B; Zhang J; Zong W; Chen S; Zong Z; Zeng X; Zhang H
    Front Immunol; 2023; 14():994698. PubMed ID: 36923402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
    Wu Y; Yi M; Niu M; Mei Q; Wu K
    Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monocyte-neutrophil entanglement in glioblastoma.
    Friedmann-Morvinski D; Hambardzumyan D
    J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
    Bayik D; Bartels CF; Lovrenert K; Watson DC; Zhang D; Kay K; Lee J; Lauko A; Johnson S; Lo A; Silver DJ; McGraw M; Grabowski M; Mohammadi AM; Veglia F; Fan Y; Vogelbaum MA; Scacheri P; Lathia JD
    Cancer Res; 2022 Nov; 82(22):4274-4287. PubMed ID: 36126163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
    Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
    Front Immunol; 2020; 11():571951. PubMed ID: 33117364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.